News
Inventors at the NIH National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) are seeking a licensee or collaborator for positive allosteric modulators (PAMs) of the A 3 adenosine receptor (A 3AR), a known therapeutic target. These heterocyclic chemical compounds bind to a lipid
A new funding opportunity announcement (FOA) is available to move commercially viable diagnostic inventions from NIAID and NIDDK intramural research laboratories into the marketplace. This FOA solicits Small Business Innovation Research (SBIR) grant applications for projects that further develop and
The OTT is pleased to announce that the annual report for Fiscal Year 2013 is now available for downloading. Click the icon below to download and view the report.
NIH-OTT authors report in Nature Biotechnology (Jan 2014) an analysis of FDA approved drugs and biologics that utilize inventions licensed from the NIH Intramural Research Program (IRP). Compared with other public-sector research institutions in the US, the NIH-IRP contribution has had a